大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展

doi:10.35541/cjd.20200179

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (5): 455-459.doi: 10.35541/cjd.20200179

大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展

李丹琪,楼雨晨,陶娟

华中科技大学同济医学院附属协和医院皮肤科皮肤修复与诊疗技术湖北省工程研究中心，武汉 430022

收稿日期:2020-02-26 修回日期:2020-10-14 发布日期:2022-04-29
通讯作者: 陶娟 E-mail:tjhappy@126.com
基金资助:
国家自然科学基金（81974245）

Application of high-dose intravenous immunoglobulin therapy in severe dermatoses

Li Danqi, Lou Yuchen, Tao Juan

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Center of Skin Recovery and Theranostics, Wuhan 430022, China

Received:2020-02-26 Revised:2020-10-14 Published:2022-04-29
Contact: Tao Juan E-mail:tjhappy@126.com
Supported by:
National Natural Science Foundation of China（81974245）

摘要/Abstract

摘要： 【摘要】大剂量静脉注射免疫球蛋白（IVIG）在部分难治性和危重皮肤病的治疗中疗效肯定，不良反应少。IgG的Fab段和Fc段可以通过结合各种自身抗原、自身抗体、补体等来介导特定的下游效应，以达到抗炎效果。该文综述IVIG的治疗机制，其在重症药疹、难治性皮肌炎和自身免疫性大疱病等重症皮肤病中的应用，以及特殊人群使用和不良反应等。

关键词: 免疫球蛋白类, 静脉内, 皮肤疾病, 重症皮肤病

Abstract: 【Abstract】 High-dose intravenous immunoglobulin （IVIG） has emerged as an effective treatment option for some refractory and severe dermatoses with few adverse reactions. The Fab and Fc fragments of IgG can exert anti-inflammatory effect by mediating specific downstream reactions via binding to a variety of autoantigens, autoantibodies and complements. This review summarizes action mechanisms of IVIG, focuses on the progress towards its application in severe dermatoses (such as severe drug eruption, refractory dermatomyositis and autoimmune bullous diseases) and special populations, as well as its adverse reactions.

Key words: Immunoglobulins, intravenous, Skin diseases, Severe dermatoses

李丹琪楼雨晨陶娟. 大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2022,55(5):455-459. doi:10.35541/cjd.20200179

Li Danqi, Lou Yuchen, Tao Juan. Application of high-dose intravenous immunoglobulin therapy in severe dermatoses[J]. Chinese Journal of Dermatology, 2022, 55(5): 455-459.doi:10.35541/cjd.20200179

参考文献 38

［1］	Emre S. Intravenous immunoglobulin treatment: where do dermatologists stand?［J］. Dermatol Ther, 2019,32（3）:e12854. doi: 10.1111/dth.12854.
［2］	Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence［J］. J Allergy Clin Immunol, 2017,139（3S）:S1⁃S46. doi: 10.1016/j.jaci. 2016.09.023.
［3］	Liu P, Li L, Fan P, et al. High⁃dose of intravenous immunoglobulin modulates immune tolerance in premature infants［J］. BMC Pediatr, 2018,18（1）:74. doi: 10.1186/s12887⁃018⁃1055⁃5.
［4］	Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology⁃⁃mode of action and clinical efficacy［J］. Nat Rev Neurol, 2015,11（2）:80⁃89. doi: 10.1038/nrneurol.2014.253.
［5］	Mimouni D, Blank M, Payne AS, et al. Efficacy of intravenous immunoglobulin （IVIG） affinity⁃purified anti⁃desmoglein anti⁃idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris［J］. Clin Exp Immunol, 2010,162（3）:543⁃549. doi: 10.1111/j.1365⁃2249.2010.04265.x.
［6］	Bayry J, Kaveri SV. Kill ′Em All: Efgartigimod immunotherapy for autoimmune diseases［J］. Trends Pharmacol Sci, 2018,39（11）:919⁃922. doi: 10.1016/j.tips.2018.08.004.
［7］	Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis［J］. Neurology, 2019,92（23）:e2661⁃e2673. doi: 10.1212/WNL. 0000000000007600.
［8］	Teeling JL, Jansen⁃Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia［J］. Blood, 2001,98（4）:1095⁃1099. doi: 10. 1182/blood.v98.4.1095.
［9］	Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation［J］. J Clin Invest, 2019,129（9）:3492⁃3498. doi: 10.1172/JCI130029.
［10］	Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease［J］. Cell, 2018,172（3）:564⁃577.e13. doi: 10.1016/j.cell.2017.11.041.
［11］	Enk A, Hadaschik E, Eming R, et al. European Guidelines （S1） on the use of high⁃dose intravenous immunoglobulin in dermatology［J］. J Dtsch Dermatol Ges, 2017,15（2）:228⁃241. doi: 10.1111/ddg.13013.
［12］	Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens⁃Johnson syndrome: a retrospective comparative study in China［J］. Int J Dermatol, 2009,48（10）:1122⁃1128. doi: 10.1111/j.1365⁃4632.2009.04166.x.
［13］	White KD, Abe R, Ardern⁃Jones M, et al. SJS/TEN 2017: Building multidisciplinary networks to drive science and translation［J］. J Allergy Clin Immunol Pract, 2018,6（1）:38⁃69. doi: 10.1016/j.jaip.2017.11.023.
［14］	Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis with meta⁃regression of observational studies［J］. Int J Dermatol, 2015,54（1）:108⁃115. doi: 10.1111/ijd.12423.
［15］	Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2012,167（2）:424⁃432. doi: 10.1111/j.1365⁃2133.2012.10965.x.
［16］	中国医师协会皮肤科医师分会变态反应性疾病专业委员会. 药物超敏反应综合征诊治专家共识［J］. 中华皮肤科杂志, 2018,51（11）:787⁃790. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 11.002.
［17］	Shiohara T, Mizukawa Y. Drug⁃induced hypersensitivity syndrome （DiHS）/drug reaction with eosinophilia and systemic symptoms （DRESS）: An update in 2019［J］. Allergol Int, 2019,68（3）:301⁃308. doi: 10.1016/j.alit.2019.03.006.
［18］	朱伟芳, 李炎冬, 斯子翔, 等. 静脉注射丙种球蛋白和糖皮质激素治疗药物超敏综合征的疗效观察［J］. 中华急诊医学杂志, 2013,22（9）:1054⁃1056. doi: 10.3760/cma.j.issn.1671⁃0282. 2013.09.031.
［19］	Galimberti F, Kooistra L, Li Y, et al. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis［J］. Clin Exp Dermatol, 2018,43（8）:906⁃912. doi: 10.1111/ced. 13607.
［20］	Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. J Dtsch Dermatol Ges, 2016,14（3）:321⁃338. doi: 10.1111/ddg.12909.
［21］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［22］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10.1016/ j.jaad.2018.02.021.
［23］	Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety［J］. Am J Clin Dermatol, 2010,11（5）:315⁃326. doi: 10.2165/11533290⁃00000 0000⁃00000.
［24］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［25］	Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin［J］. Front Immunol, 2018,9:1189. doi: 10.3389/fimmu.2018.01189.
［26］	Ahmed AR, Shetty S, Kaveri S, et al. Treatment of recalcitrant bullous pemphigoid （BP） with a novel protocol: a retrospective study with a 6⁃year follow⁃up［J］. J Am Acad Dermatol, 2016,74（4）:700⁃708.e3. doi: 10.1016/j.jaad.2015.11.030.
［27］	Ahmed AR, Nguyen T, Kaveri S, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow⁃up［J］. Int Immunopharmacol, 2016,34:25⁃31. doi: 10.1016/j.intimp.2016.02.013.
［28］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［29］	Nieto⁃Aristizábal I, Martínez T, Urbano MA, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a single⁃center experience with 63 patients［J］. Lupus, 2019,28（13）:1566⁃1570. doi: 10.1177/0961203319883 680.
［30］	Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases［J］. Rheumatology （Oxford）, 2015,54（3）:383⁃391. doi: 10.1093/rheumatology/keu429.
［31］	Wong PH, White KM. Impact of Immunoglobulin therapy in pediatric disease: a review of immune mechanisms［J］. Clin Rev Allergy Immunol, 2016,51（3）:303⁃314. doi: 10.1007/s12016⁃015⁃8499⁃2.
［32］	Jee SJ, Kim JH, Baek HS, et al. Long⁃term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis［J］. Allergy Asthma Immunol Res, 2011,3（2）:89⁃95. doi: 10.4168/aair.2011.3.2.89.
［33］	Rademaker M, Agnew K, Andrews M, et al. Managing atopic dermatitis with systemic therapies in adults and adolescents: an Australian/New Zealand narrative［J］. Australas J Dermatol, 2020,61（1）:9⁃22. doi: 10.1111/ajd.13141.
［34］	Tekin B, Yücelten AD. Infantile bullous pemphigoid treated using intravenous immunoglobulin: case report and review of the literature［J］. Pediatr Dermatol, 2015,32（5）:723⁃726. doi: 10. 1111/pde.12635.
［35］	Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy［J］. Am J Clin Dermatol, 2018,19（3）:391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0.
［36］	Ahmed AR, Gürcan HM. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris［J］. J Eur Acad Dermatol Venereol, 2011,25（9）:1073⁃1079. doi: 10.1111/j.1468⁃3083.2010.03925.x.
［37］	Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy［J］. Front Immunol, 2018,9:1299. doi: 10.3389/fimmu. 2018.01299.
［38］	Hoffmann J, Enk AH. High⁃Dose Intravenous immunoglobulin in skin autoimmune disease［J］. Front Immunol, 2019,10:1090. doi: 10.3389/fimmu.2019.01090.

[1]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[2]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[3]	张国毅, 龚向东, 朱伯堃, 柳传霞, 景玲华, 徐金玉. 2019年中国医学科学院皮肤病医院门诊病种分析[J]. 中华皮肤科杂志, 2022, 55(2): 150-152.
[4]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识（2022）[J]. 中华皮肤科杂志, 2022, 55(1): 1-11.
[5]	姜沛彧张嘉文刘子菁王小燕刘韵祎刘乙萱许阳. 光生物调节的基本原理及其在皮肤科的应用[J]. 中华皮肤科杂志, 2022, 55(1): 84-87.
[6]	龙海蒋丽邱月棨姚南刘力聪谢昱明熊峰谭思齐匡琪琪尤睿璇柴可罗鑫龙浩君忻悦郭子瑜王佳琪谭怡忻张庆张桂英李亚萍苏玉文肖嵘陆前进, . 皮肤科病房危重症1 057例临床分析[J]. 中华皮肤科杂志, 2021, 54(9): 790-797.
[7]	胡枫陈柳青王巍郑芳. COVID-19流行期间武汉某医院皮肤科门诊患者流行病学特点及疾病谱分析[J]. 中华皮肤科杂志, 2021, 54(8): 719-722.
[8]	应洁雅相文忠宋秀祖. 代谢综合征与皮肤病[J]. 中华皮肤科杂志, 2021, 54(7): 642-645.
[9]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 382-390.
[10]	康莉刘艳郑云燕鞠梅张亚美毕志刚芦桂青. 马血清破伤风抗毒素与马破伤风免疫球蛋白F（ab′）₂引起的皮肤迟发型变态反应临床分析[J]. 中华皮肤科杂志, 2021, 54(3): 226-228.
[11]	叶瑞贤薛如君梁景耀刘焕颜熊绮颖董良娇张锡宝. microRNA在炎症性皮肤病中作用的研究进展[J]. 中华皮肤科杂志, 2021, 54(2): 178-182.
[12]	刘沛石磊王秀丽. 皮肤疾病光动力治疗的光源和照光参数选择[J]. 中华皮肤科杂志, 2021, 54(11): 1015-1018.
[13]	朱蓓蓓李婧黄慧瑶李宁刘利军张丽华宦静倪琪侯伟刘毅杨雪源. 2020年中国皮肤病药物临床试验分析[J]. 中华皮肤科杂志, 2021, 54(11): 1001-1004.
[14]	郑玉灿孔桂萍金玉李玫. FAM111B基因突变致遗传性纤维性皮肤异色病伴跟腱挛缩、肌病和肺纤维化一例[J]. 中华皮肤科杂志, 2021, 54(11): 973-977.
[15]	陈伟谢恒李利. 胞外囊泡在皮肤科的研究进展和应用前景[J]. 中华皮肤科杂志, 2021, 54(10): 910-914.

大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展

Application of high-dose intravenous immunoglobulin therapy in severe dermatoses

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

Metrics

本文评价

推荐阅读 10